P. Saddier

发表

Health care utilization and cost burden of herpes zoster in a community population.

B. Yawn, P. Wollan, L. Sy, 2009, Mayo Clinic proceedings.

Health Care Utilization and Cost Burden of Herpes Zoster in a Community Population ORIGINAL ARTICLE

B. Yawn, P. Wollan, L. Sy, 2009 .

Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older Adults

K. Schmader, M. Levin, M. Ciarleglio, 2010, Journal of the American Geriatrics Society.

Impact of Vaccination on the Epidemiology of Varicella: 1995–2009

E. Lewis, S. Black, B. Fireman, 2014, Pediatrics.

Long-term Effectiveness of Varicella Vaccine: A 14-Year, Prospective Cohort Study

E. Lewis, S. Black, B. Fireman, 2013, Pediatrics.

Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program.

S. Black, H. Shinefield, P. Ray, 2008, The Journal of infectious diseases.

Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.

N. Halsey, Z. Popmihajlov, A. Gershon, 2017, Vaccine.

Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort

J. Chodakewitz, D. Denning, A. Saah, 2010, European Journal of Clinical Microbiology & Infectious Diseases.

Herpes Zoster and Postherpetic Neuralgia

G. Wasner, R. Baron, Robert W. Johnson, 2008, Drugs & aging.

Postherpetic neuralgia: epidemiology, pathophysiology and management

G. Wasner, R. Baron, Robert W. Johnson, 2007, Expert review of neurotherapeutics.

Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study

C. Velicer, P. Saddier, J. Seeger, 2022, Human vaccines & immunotherapeutics.

Practice of Epidemiology Long-TermEffectiveness of the Live Zoster Vaccine in Preventing Shingles : A Cohort Study

E. Lewis, B. Fireman, J. Bartlett, 2017 .

Cost of varicella in France: a study in day care centers.

H. Guess, D. Weber, D. Floret, 1998, The Journal of infectious diseases.

Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.

T. Cheetham, S. Jacobsen, T. Tran, 2009, Vaccine.

Nocturnal Melatonin Excretion is Decreased in Patients With Migraine Without Aura Attacks Associated With Menses

G. Chazot, B. Claustrat, J. Brun, 1995, Cephalalgia : an international journal of headache.

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world

Yadong Cui, P. Saddier, Harshila Patel, 2017, Human vaccines & immunotherapeutics.

Complications of herpes zoster in cancer patients

B. Yawn, L. Habel, M. Horberg, 2014, Scandinavian journal of infectious diseases.

A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.

B. Yawn, P. Wollan, J. S. St. Sauver, 2007, Mayo Clinic proceedings.

Herpes zoster recurrences more frequent than previously reported.

B. Yawn, P. Wollan, J. S. St. Sauver, 2011, Mayo Clinic proceedings.

Risk of cancer from azathioprine therapy in multiple sclerosis

P. Adeleine, G. Aimard, C. Confavreux, 1996, Neurology.

Work and productivity loss related to herpes zoster

L. Sy, J. Pellissier, P. Saddier, 2011, Journal of medical economics.

The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults

K. Schmader, C. Pieper, M. Levin, 2007, The Clinical journal of pain.

The incidence of herpes zoster in a United States administrative database

R. Itzler, J. Pellissier, P. Saddier, 2005, Journal of General Internal Medicine.

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.

S Suissa, S. Vukusic, S. Suissa, 2001, The New England journal of medicine.

Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance

D. Gutsch, M. Robertson, P. Saddier, 2012, Human vaccines & immunotherapeutics.

Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study

E. Lewis, B. Fireman, J. Bartlett, 2017, American journal of epidemiology.

EFFECTIVENESS OF LIVE ZOSTER VACCINE IN PREVENTING POSTHERPETIC NEURALGIA (PHN)

B. Fireman, J. Bartlett, E. Bresnitz, 2016 .

Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012-2016.

C. Velicer, P. Saddier, J. Seeger, 2021, Vaccine.

Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use.

N. Klein, N. Lewis, C. Velicer, 2022, Vaccine.

Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.

E. Lewis, B. Fireman, J. Bartlett, 2019, Vaccine.

Safety of Zostavax™--a cohort study in a managed care organization.

B. Fireman, T. Tran, J. Bartlett, 2012, Vaccine.

Frequency of Herpes Zoster Recurrence–Reply–I

B. Yawn, J. Sauver, P. Wollan, 2011 .

Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States.

C. Velicer, P. Saddier, J. Seeger, 2022, Vaccine.